16 results about "Uveitis" patented technology

The present invention belongs to the technical field of medicine, and in particular relates to a novel aromatic ring derivative containing an amide substitution or a pharmaceutically acceptable salt thereof. The diseases comprise, but are not limited to, inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, and uveitis. The structure of the compound of formula I is as described in the claims and the description. The aromatic ring derivative containing an amide substitution provided in the present invention is used as a novel TYK2 inhibitor, has a good TYK2 inhibitory effect, has a good therapeutic effect in an in vivo model of psoriasis and asthma animals, and has good druggability, high stability and good safety.

The present application provides an acesulfame implant which is stable, safe and can achieve at least 6 months of sustained release, can effectively treat various eye diseases including but not limited to glaucoma, cataract, retinal vein obstruction (RVO), uveitis, diabetic macular edema (DME) and age-related macular degeneration (wAMD and nAMD), etc., avoids repeated administration, reduces the formation of side effects, reduces the cost of drug use, and meets the high stability required by drug preparation in production, storage and transportation, has good application prospect, and meets the unmet clinical needs.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

The application discloses application of NAMPT as a target point in preparation of a medicine for treating uveitis, wherein the medicine contains a NAMPT inhibitor, the NAMPT inhibitor is FK866, and the NAMPT inhibitor is used for inhibiting expression or activity of NAMPT, thereby down-regulating CD4 + The Hif1a expression level of T cells reestablishes the Teff / Treg balance, and inhibits occurrence and development of uveitis, thereby providing a brand-new drug target for treatment of uveitis. Meanwhile, the application verifies that the NAMPT-HIF1a axis has conservation and potential treatment value in uveitis through experiments, proves that NAMPT can become a potential treatment target of uveitis, and proposes that a NAMPT inhibitor is used for preparing the medicine for treating uveitis, thereby laying a solid theoretical and experimental foundation for development of a new generation of targeted medicine for treating uveitis.

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.

This specification describes modified monoterpene TRPM8 activating compounds. In particular, the compounds provided herein affect the function of ion channels in cells and are useful as therapeutic agents or in conjunction with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions, including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth such as cancer. This specification describes Ca 2+ This is an N-substituted C6 cyclylcarboxamide compound that affects intracellular ion transport, such as ions, and is useful as a therapeutic agent or in combination with one or more additional therapeutic agents.

The invention discloses an exosome protein as a molecular marker for diagnosing uveitis, and belongs to the technical field of molecular diagnos.The molecular marker is isocitrate dehydrogenase 3a (IDH3a) protein in exosomes, and the sequence of the isocitrate dehydrogenase 3a (IDH3a) protein is shown as SEQ ID NO.1. The molecular marker has the advantages of being high in non-invasiveness, high in specificity and sensitivity, easy and convenient to operate, low in cost and the like, early screening can be achieved, and the application prospect is wide. And the method is suitable for popularization and application in clinical laboratories.

The present invention relates to a composition comprising a peptide derived from S- Retinol dehydrogenase (S-antigen, S-Ag). The composition or peptide can be used to prevent and / or inhibit S-Ag autoimmunity, can be used to treat and / or prevent uveitis.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

This invention relates to the field of image segmentation technology and discloses a method for segmenting uveitis lesions based on a U-shaped encoder-decoder network. First, a multi-branch feature fusion module is constructed as a basic unit, stacked to form a multi-scale feature enhancement encoder. Second, a frequency domain cross-layer feature fusion module is designed in the skip connections, utilizing Haar wavelet decomposition to extract boundary information and combining spatial and channel attention to filter and fuse features. A hybrid Mamba interaction bottleneck module is set at the top of the encoder to align and aggregate multi-level deep features, obtain global context through visual Mamba, and perform mutual correction of global and local features using a joint attention map. In the decoding stage, an uncertainty-aware recursive gating module is introduced, using the Shannon entropy output of the prediction head as the uncertainty map to dynamically modulate the initial gating generated by the gating network, achieving adaptive control of the intensity of shallow detail introduction.